Chlorhexidine gluconate is an antimicrobial rinse used to reduce bacteria in the mouth to treat and prevent gum disease, and it's also used as a skin cleanser before surgery or for wound care to prevent infection.[1] Peridex is currently being investigated across 18 indications[3], with its most advanced program in Phase 3.[1]
Peridex is one of 182 small molecule programs targeting Staphylococcal Skin Infections. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
139 competitors in Trial
Opdivo
Yervoy
Camptosar
Eloxatin
Vectibix
Perjeta
Platinol
Tarceva
Herceptin
Xeloda
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
HIBISTAT
NDA NDA018300
Jan 1, 1982
HIBICLENS
NDA NDA017768
Jan 1, 1982
HIBICLENS
NDA NDA018423
Dec 24, 1984
EXIDINE
NDA NDA019127
Dec 24, 1984
DYNA-HEX 4
NDA NDA019125
Dec 17, 1985
EXIDINE
NDA NDA019421
Dec 17, 1985
DYNA-HEX 2
NDA NDA019422
Jul 22, 1986
CHG SCRUB
NDA NDA019258
Aug 13, 1986
PERIDEX
NDA NDA019028
Mar 27, 1987
CHLORHEXIDINE GLUCONATE
NDA NDA019490
Dec 2, 1988
PHARMASEAL SCRUB CARE
NDA NDA019793
Mar 31, 1989
BIOSCRUB
NDA NDA019822
Sep 11, 1997
CHLORHEXIDINE GLUCONATE
NDA NDA020111
May 15, 1998
PERIOCHIP
NDA NDA020774
Apr 25, 2005
CHLORHEXIDINE GLUCONATE
NDA NDA021669
Nov 20, 2018
READYPREP CHG
NDA NDA207964
Sources
Details